ENDYMION 2 open-label extension of phase 3 soticlestat trials in Dravet syndrome and Lennox-Gastaut syndrome

Phase 3, open-label, single-arm trial of soticlestat in Dravet syndrome and Lennox-Gastaut syndrome (LGS), sponsored by Takeda. Primary endpoints: Number of Participants With At Least One Treatment Emergent Adverse Event (TEAE), Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) Score and 4 more. Started Mar 2022; status: completed.